What is Unchained Labs?
Founded in 2014 and headquartered in Pleasanton, California, Unchained Labs is a specialized developer of high-throughput analytical tools designed to solve complex challenges in biologics and gene therapy research. The company gained significant market traction with the launch of Optim, the industry's first multiplex protein stability platform. By focusing on the intersection of hardware innovation and biological research, Unchained Labs provides essential infrastructure that enables researchers to streamline workflows, improve data accuracy, and reduce the time-to-market for critical therapeutic developments. Its market position is defined by a commitment to building problem-tackling products that address the specific, high-stakes needs of modern laboratory environments.
How much funding has Unchained Labs raised?
Unchained Labs has raised a total of $285M across 6 funding rounds:
Series A
$25M
Series B
$25M
Series C
$13M
Series D
$17M
Unspecified
$50M
Debt
$155M
Series A (2015): $25M with participation from Canaan Partners, Novo Ventures, and TPG Biotech
Series B (2016): $25M led by Canaan Partners, TPG Biotech, and Novo Ventures
Series C (2017): $13M supported by Novo Ventures, TPG Biotech, and Canaan Partners
Series D (2018): $17M featuring Novo Ventures, TPG Biotech, and Canaan Partners
Unspecified (2019): $50M backed by Silicon Valley Bank
Debt (2021): $155M with participation from Golub Capital and MidCap Financial
Key Investors in Unchained Labs
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
TPG Biotech
A global alternative asset management firm that partners with businesses to drive long-term value creation through diversified investment strategies across multiple industries.
Canaan Partners
An early-stage venture capital firm that invests in technology and healthcare companies, supporting founders from seed through growth stages in biopharma and digital health.
What's next for Unchained Labs?
With a robust history of capital acquisition, Unchained Labs is well-positioned to leverage its recent strategic investment to expand its product portfolio and deepen its market penetration. The company's transition from early-stage venture backing to more sophisticated debt and equity structures suggests a focus on operational scaling and potential inorganic growth opportunities. Moving forward, the firm is expected to prioritize the integration of its analytical platforms into broader clinical research workflows, further cementing its role as a foundational partner for global biopharma organizations. The strategic deployment of these funds will likely center on R&D acceleration and the global expansion of its commercial footprint, ensuring that its technological edge remains sharp in an increasingly competitive life sciences landscape.
See full Unchained Labs company page
